

DATE June 14, 2018

To,

1. Gilead Sciences, Inc.

333 Lakeside Drive, Foster City
California 94404, USA

2. Medicines Patent Pool

Rue de Varembe 7
1202 Geneva, Switzerland

Sub: Termination of Tenofovir Disoproxil Fumarate (TDF), elvitegravir (EVG) and cobicistat (COBI)


Ref: License Agreement dated November 3 , 2017, executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Shanghai Desano Pharmaceuticals Co. Ltd.

Dear Sir/Madam,

In accordance with section 10.5 of the above License Agreement, We, Shanghai Desano Pharmaceuticals Co. Ltd., hereby provides notice of termination of the license for Tenofovir Disoproxil Fumarate (TDF) elvitegravir(EVG) and cobicistat(COBI) effective immediately.

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely,



On behalf of

Shanghai Desano Pharmaceuticals Co. Ltd